Huntington Bancshares (NASDAQ:HBAN – Free Report) had its price objective increased by Jefferies Financial Group from $20.00 to $22.00 in a research report report published on Friday morning,MarketScreener reports. The brokerage currently has a buy rating on the bank’s stock. A number of other equities analysts have also recently issued reports on HBAN. Citigroup boosted […]

Mirum Pharmaceuticals (NASDAQ:MIRM – Free Report) had its target price lifted by Stifel Nicolaus from $92.00 to $98.00 in a research note published on Tuesday morning,Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock. Other equities research analysts have also recently issued research reports about the stock. Leerink Partners set a $100.00 […]

BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its price target raised by Leerink Partners from $75.00 to $86.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has an outperform rating on the stock. Several other analysts also recently commented on the stock. Raymond James Financial reaffirmed an “outperform” rating and […]

Royalty Pharma (NASDAQ:RPRX – Free Report) had its price target boosted by TD Cowen from $42.00 to $45.00 in a research note released on Thursday,Benzinga reports. TD Cowen currently has a buy rating on the biopharmaceutical company’s stock. A number of other analysts have also recently commented on the company. Morgan Stanley cut their price […]

Ligand Pharmaceuticals (NASDAQ:LGND – Free Report) had its price objective increased by Royal Bank Of Canada from $234.00 to $235.00 in a research report sent to investors on Wednesday,Benzinga reports. Royal Bank Of Canada currently has an outperform rating on the biotechnology company’s stock. Several other research firms have also recently weighed in on LGND. […]

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price boosted by Wells Fargo & Company from $460.00 to $515.00 in a research report sent to investors on Wednesday,Benzinga reports. The brokerage currently has an overweight rating on the pharmaceutical company’s stock. Several other analysts have also recently commented on VRTX. Evercore ISI decreased their […]

Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price objective raised by Wells Fargo & Company from $700.00 to $745.00 in a report published on Wednesday morning,Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the biopharmaceutical company’s stock. Several other equities research analysts also recently commented on the stock. Jefferies […]